Neuronetics Inc
Neuronetics operates with a high debt-to-equity ratio of 3.08, indicating a capital structure heavily reliant on debt financing. The company holds $42.64 million in cash and equivalents, but this is offset by $59.76 million in long-term debt, resulting in a net cash position of -$17.12 million. The current ratio of 2.58 suggests adequate short-term liquidity, but the negative operating cash flow of -$16.98 million and free cash flow of -$9.85 million highlight ongoing cash burn. Profitability metrics are weak, with a net loss of $9.83 million and an operating loss of $8.51 million. Return on equity is -50.72%, and return on assets is -10.16%, both significantly below industry norms for medical equipment firms. Gross profit of $12.18 million represents 74% of revenue, but this is insufficient to cover operating expenses. The company derives revenue primarily from the sale and rental of its NeuroStar TMS Therapy system, with geographic exposure concentrated in the United States. No material international revenue is disclosed, and the business is highly dependent on a single product line. Outlook for the current fiscal year shows a continuation of losses, with no material revenue growth expected. The company has not provided forward-looking guidance, and historical revenue trends show little to no growth. Analysts have assigned a mean price target of $4.33, but the absence of strong-buy ratings reflects skepticism about near-term value realization. Risk factors include high leverage, negative cash flows, and dependence on a single product. The risk assessment flags a medium liquidity risk and low dilution risk, though the negative net cash position raises concerns about financial flexibility. No recent equity issuance or dilutive events are reported. Recent filings and transcripts show no material changes in business strategy or product pipeline. The company remains focused on expanding NeuroStar adoption through clinical studies and physician education. No new product launches or regulatory approvals were disclosed in the latest reports.
Business. Neuronetics Inc develops and commercializes non-invasive medical devices for the treatment of neurological and psychiatric disorders, primarily through its NeuroStar TMS Therapy system.
Classification. Neuronetics is classified in the Advanced Medical Equipment & Technology industry within the Healthcare Services & Equipment business sector, with a confidence level of 0.92.
- Neuronetics is capital-intensive with a debt-to-equity ratio of 3.08 and negative net cash.
- The company is unprofitable, with a net loss of $9.83 million and ROE of -50.72%.
- Revenue is concentrated in a single product and domestic market, limiting diversification.
- Analysts assign a mean price target of $4.33, but no strong-buy ratings are issued.
- Liquidity risk is medium, and dilution risk is low, though cash burn remains a concern.
- --
- ## RATIONALES
- ```json
- Net cash is negative after subtracting total debt.